Fiera Capital Corp Makes New $517,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)

Fiera Capital Corp bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,444 shares of the biotechnology company's stock, valued at approximately $517,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its holdings in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock valued at $692,748,000 after purchasing an additional 22,978 shares in the last quarter. LSV Asset Management raised its holdings in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock valued at $307,837,000 after purchasing an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company's stock valued at $186,656,000 after purchasing an additional 22,683 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock valued at $178,972,000 after purchasing an additional 92,240 shares in the last quarter. Finally, Swedbank AB bought a new position in shares of United Therapeutics during the 1st quarter valued at $97,316,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Activity

In related news, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 96,422 shares of company stock worth $35,251,428. Company insiders own 11.90% of the company's stock.

United Therapeutics Trading Down 1.6 %

UTHR traded down $6.67 on Monday, hitting $403.33. 196,649 shares of the stock traded hands, compared to its average volume of 463,638. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a market capitalization of $18.01 billion, a PE ratio of 18.01, a P/E/G ratio of 1.20 and a beta of 0.56. The business has a fifty day moving average price of $359.20 and a two-hundred day moving average price of $323.38.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period in the prior year, the company posted $5.38 EPS. The company's revenue was up 22.9% compared to the same quarter last year. On average, equities research analysts forecast that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on UTHR. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Wells Fargo & Company boosted their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 20th. Finally, Jefferies Financial Group boosted their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.